UniQure Stock Plunges 48% as Huntington's Drug Data Misses Statistical Significance
QURE has more than doubled off its 52-week low of $8.73.
Summary
UniQure shares crashed 48% to $20.50 premarket after 48-month Phase I/II data for AMT-130 in Huntington's disease showed only 44% slowing of disease progression and missed statistical significance. The company insists the data still support approval, pointing to statistically strong 36-month results for all 15 high-dose patients, which form the basis of its BLA. This follows the BLA submission announced earlier this month and the FDA's prior skepticism about Phase I/II data sufficiency. The market is clearly questioning whether the FDA will accept the application given the mixed long-term results. Watch for any FDA response to the BLA and further analysis of the dropout-adjusted data.
At the time of this announcement, QURE was trading at $22.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $8.73 to $71.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.